Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03878420
Recruitment Status : Recruiting
First Posted : March 18, 2019
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
LumiThera, Inc.

Brief Summary:
This LIGHTSITE II study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.

Condition or disease Intervention/treatment Phase
Dry Age-related Macular Degeneration Device: Valeda PBM treatment Device: Valeda Sham treatment Not Applicable

Detailed Description:

This study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. The target enrollment is 96 subjects in up to 10 centers in Europe, randomized at a 1:2 ratio into 2 groups: Sham Treatment (S-1) and PBM Treatment (T-2). Once 96 subjects have been enrolled in the study, if there are less than 144 eyes that qualify for the study, additional subjects will be enrolled until 144 eyes have been included in the study.

S-1 will receive 3 sham treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4 and 8. T-2 will receive 3 PBM treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4 and 8. Each treatment series will total 9 treatments. Neither the subject nor the study staff will know which treatment the subject has been assigned.

Subjects will receive standard visual outcome measurements including Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA, CSV-1000E contrast sensitivity (CS) and the Radner Reading Test prior to and following each treatment series as well as eye exams, fundus photographs, Heidelberg OCT and FAF imaging and optional Optos Ultra Wide Field (UWF) imaging of the retina at selected time intervals. Subjects will also complete the Visual Function Questionnaire 25 (VFQ-25) at selected time intervals.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Valeda Light Delivery System
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE II)
Actual Study Start Date : February 14, 2019
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PBM Treatment
The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
Device: Valeda PBM treatment
The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.

Sham Comparator: Sham Treatment
The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
Device: Valeda Sham treatment
The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.




Primary Outcome Measures :
  1. Best Corrected Visual Acuity [ Time Frame: Month 9 ]
    The primary efficacy endpoint will be the change in BCVA from Baseline to Month 9 as assessed using the ETDRS BCVA chart.


Secondary Outcome Measures :
  1. Best Corrected Visual Acuity [ Time Frame: Month 9 ]
    The first of the secondary analyses will test the difference between the sham-treated and PBM-treated subjects in mean change from baseline (pre-treatment) to Month 9 in BCVA.

  2. Contrast Sensitivity [ Time Frame: Month 9 ]
    The second of the secondary analyses will test the difference between the sham-treated and PBM-treated subjects in mean change from baseline (pre-treatment) to Month 9 in contrast sensitivity at 18 cycles/degree (CPD).

  3. Impact on Central Drusen Volume by OCT [ Time Frame: Month 10 ]
    The analyses will first examine change from the screening visit in central Drusen volume

  4. Impact on Central Drusen Thickness by OCT [ Time Frame: Month 10 ]
    The analyses will then examine change from the screening visit in central Drusen Thickness



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female at least 50 years of age at Screening visit
  • Subjects with ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to 20/32). *If the subject meets this criterion at the Screening Visit but is outside the letter score by up to two letters at Baseline, the subject may be entered in the study.
  • Subjects with a diagnosis of dry AMD as defined by the presence of drusen (regular or reticular pseudodrusen) and/or geographic atrophy (GA) visible on two of the following: color fundus images, OCT and/or Heidelberg FAF
  • Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
  • Subject is informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines

Exclusion Criteria:

  • Current or history of neovascular maculopathy that includes any of the following:

    1. Choroidal neovascularization (CNV) defined as pathologic angiogenesis originating from the choroidal vasculature that extends through a defect in Bruch's membrane
    2. Serous and/or hemorrhagic detachment of the neurosensory retina or retinal pigment epithelial (RPE)
    3. Retinal hard exudates (a secondary phenomenon resulting from chronic intravascular leakage)
    4. Subretinal and sub-RPE fibrovascular proliferation
    5. Disciform scar (subretinal fibrosis)
  • Presence of center involving GA within the central ETDRS 1 mm diameter at Screening
  • Media opacities, including cataracts, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the next 24 months.
  • Posterior capsule opacification, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require surgery in the study eye in the next 24 months
  • Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3 months prior to Screening
  • Ocular disorder or disease that partially or completely obstructs the pupil (e.g. posterior synechia in uveitis)
  • Visually significant disease in any ocular structure apart from dry AMD (e.g. diabetic macular edema, glaucoma (using >2 eye drop medications, uncontrolled IOP and/or central/paracentral visual field loss), glaucoma surgery, active uveitis, active vitreous disease, intraocular tumor, retinal vascular diseases)
  • Has a serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study
  • Presence of or history of malignancy within the past 5 years other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ
  • Is non-ambulatory
  • Presence or history of known light sensitivity to yellow light, red light, or near infrared radiation (NIR), or if there is a history of light activated CNS disorders (e.g. epilepsy, migraine)
  • Use of any photosensitizing agent (e.g. topicals, injectables) within 30 days of treatment without consulting subject's physician
  • History of drug, alcohol or substance abuse within 3 months prior to Screening
  • Has received an investigational drug or treatment with an investigational device within 3 months prior to Screening
  • If on any anti-oxidant or vitamin Age-Related Eye Disease Study (AREDS) supplement for dry AMD, has not been stabilized for a minimum of 1 month prior to Screening. Subjects are considered to be stable if they are taking the AREDS supplements consistently as prescribed by their treating doctor.
  • Has received Low Vision Rehab/Therapy within 30 days prior to Screening or intends to receive during the study
  • In the opinion of the Investigator, is unlikely to comply with the study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03878420


Contacts
Layout table for location contacts
Contact: Clark Tedford, PhD 3605365119 ctedford@lumithera.com
Contact: Cindy Croissant, MBA 8583971021 ccroissant@lumithera.com

Locations
Layout table for location information
France
Institut ophtalmologique de l'Ouest- Clinique jules VERNE Recruiting
Nantes, France
Contact: Sander Marie-Sylvie    +33681084766    ms.sander@ophtalliance.fr   
Contact: Tanguy-Loup BIZEAU    +33645096083    t.bizeau@ophtalliance.fr   
Principal Investigator: Xavier Zanlonghi, MD         
Germany
Universitätsklinikum Freiburg- Klinik für Augenheilkunde Recruiting
Freiburg, Germany, 79106
Contact: Fanni Molnar, MD    0049 761 270-40231    fanni.molnar@uniklinik-freiburg.de   
Contact: Christine Kremer    0049 761 270-40231    christine.kremer@uniklinik-freiburg.de   
Principal Investigator: Fanni Molnar, MD         
Klinik fur Ophthalmologie, Universitatsklinikum Schleswig-Holstein Recruiting
Kiel, Germany
Contact: Christoph Ehlken, FEBO    +49 431 24231    Christoph.ehlken@uksh.de   
Principal Investigator: Johann Roider, MD         
Universitaetsmedizin Mainz- Augenklinik Recruiting
Mainz, Germany, 55131
Contact: Sabine Buchner, M.Sc    0049 6131 17 8355    sabine.buchner@unimedizin-mainz.de   
Contact: Christine Nolde    0049 6131 17 7509    christine.nolde@unimedizin-mainz.de   
Principal Investigator: Katrin Lorenz, MD         
Italy
Osprdalr San Raffaele Recruiting
Milano, Italy
Contact: Calcagno Francesca       calcagno.francesca@hsr.it   
Principal Investigator: Maurizio Parodi, MD         
Spain
Institut Català de Retina Recruiting
Barcelona, Spain
Contact: Antonio Morilla-Grasa, PhD    +34 932531647    amorilla@icrcat.com   
Contact: Virginia García-del Puerto    +34 932531647    vgarcia@icrcat.com   
Principal Investigator: Ignasi Jürgens, MD         
United Kingdom
James Paget University Recruiting
Great Yarmouth, United Kingdom, NR31 6LA
Contact: Ben Burton, MD       Ben.Burton@jpaget.nhs.uk   
Contact: Karen Eade         
Principal Investigator: Ben Burton, MD         
Peterborough City Hospital Recruiting
Peterborough, United Kingdom, PE3 9GZ
Contact       nwanglaift.ophthalmlogyresearch@nhs.net   
Principal Investigator: Dan Hornan, MD         
Sponsors and Collaborators
LumiThera, Inc.

Layout table for additonal information
Responsible Party: LumiThera, Inc.
ClinicalTrials.gov Identifier: NCT03878420     History of Changes
Other Study ID Numbers: CSP003
First Posted: March 18, 2019    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by LumiThera, Inc.:
Dry AMD
Photobiomodulation
Visual Acuity
Contrast Sensitivity
Optical Coherence Tomography
Drusen

Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases